Clinical trial

Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)

NCT06926790

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-02-17

PhasePHASE2

Study timeline

Study start (actual)2025-02-17Date precision: day

Registry last updated2025-04-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Cancer - Non Small Cellunresolved

Interventions

Nivolumab & IpilimumabDRUG

Sponsors & collaborators

The First Affiliated Hospital of Guangzhou Medical Universitylead sponsor

Mapped research locations

GuangzhouChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06926790 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.